Akebia Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Akebia Therapeutics kazanç ve gelirinin sırasıyla yıllık 20.3% ve 2.5% oranında artması tahmin edilirken, EPS'nin yıllık 20.5% oranında büyümesi bekleniyor.
Anahtar bilgiler
20.3%
Kazanç büyüme oranı
20.48%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 25.2% |
| Gelir büyüme oranı | 2.5% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 30 Jun 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 24
Market Anger vs. Valuation Disconnect
The current low price is driven by market fury over management's failure to handle an expected product transition. By reacting emotionally to a temporary operational blunder, the market has created a massive disconnect between Akebia's current price and its true intrinsic value.
Anlatı Güncellemesi • Jun 22
AKBA: Extended Kidney Patent Protection Will Support Future Upside Potential
Analysts have adjusted their price target for Akebia Therapeutics to $6.00, citing updated assumptions about the discount rate, revenue growth, profit margin, and future P/E, which together support this revised valuation view. What’s in the News for Akebia Therapeutics Akebia Therapeutics was removed from the S&P Biotechnology Select Industry Index, reflecting a change in index membership based on that provider’s criteria.Anlatı Güncellemesi • Jun 05
AKBA: Kidney Pipeline Expansion And Share Authorization Increase Will Support Upside Potential
Analysts have maintained their $6.00 price target for Akebia Therapeutics, citing only minor updates in their underlying assumptions on discount rate, revenue growth, profit margins, and future P/E as the reason for no change in the headline number. What's in the News Akebia Therapeutics plans to seek shareholder approval to amend its Ninth Amended and Restated Certificate of Incorporation to increase authorized capital stock to 525,000,000 shares and authorized common stock to 500,000,000 shares.Anlatı Güncellemesi • May 19
AKBA: Kidney Pipeline Advances Will Offset Renal Channel Inventory Adjustments
Narrative Update on Akebia Therapeutics Analysts have trimmed their price target on Akebia Therapeutics stock by $1 to $4, citing a new US Renal Care dosing protocol that they say reduced channel inventory by about $4.5M to $5.0M and contributed to Vafseo revenue recognized in Q4 coming in $5M to $6M lower than they had expected. Analyst Commentary Bullish analysts are framing the recent price target trim as a fine tuning of expectations rather than a shift in the core thesis on Akebia Therapeutics.Analiz Makalesi • May 11
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results
There's been a major selloff in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares in the week since it released its...Anlatı Güncellemesi • May 03
AKBA: Kidney Pipeline Progress Will Drive Future Upside Despite Inventory Headwinds
Narrative Update on Akebia Therapeutics Analysts have reduced Akebia Therapeutics' price target by $1 to $4, citing updated expectations for Vafseo revenue after a new US Renal Care dosing protocol and related channel inventory adjustments. Analyst Commentary Bullish analysts appear focused on how recent pricing and dosing updates feed into the long term opportunity for Vafseo, even as they recalibrate near term expectations.
Anlatı Güncellemesi • Apr 19
AKBA: Renal Dosing Reset And Inventory Shift Will Support Future Profitability
Akebia Therapeutics' consensus analyst price target has shifted lower, with moves such as a cut from $5 to $4 at BTIG and a $2 reduction at Piper Sandler as analysts factor in recent Vafseo revenue shortfalls tied to US Renal Care's updated dosing protocol and related channel inventory effects. Analyst Commentary Bearish analysts are reassessing Akebia Therapeutics after Vafseo revenue recognized in Q4 came in at about US$5m to US$6m, which they link to a new US Renal Care protocol and an estimated US$4.5m to US$5m decrease in channel inventory.
Anlatı Güncellemesi • Apr 05
AKBA: Phase 2 Kidney Trial Will Offset Dosing Protocol Revenue Reset
Akebia Therapeutics' Street price targets have been trimmed by analysts, with one firm moving from $5 to $4 as they factor in lower than expected Q4 Vafseo revenue tied to a new US Renal Care dosing protocol and related channel inventory reductions. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after trimming price targets.Anlatı Güncellemesi • Mar 22
AKBA: Renal Care Dosing Reset Will Support Stronger Long Term Profitability
Akebia Therapeutics' consensus analyst price target has moved lower to $4 from $5, as analysts factor in recent updates on Vafseo revenue recognition tied to US Renal Care dosing protocols and related channel inventory adjustments. Analyst Commentary Bearish analysts are framing the lower $4 price target as a reflection of execution risk around the Vafseo launch, especially after the new US Renal Care dosing protocol affected how much revenue could be recognized in the quarter.Yeni Anlatı • Mar 13
Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio
Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.Anlatı Güncellemesi • Mar 07
AKBA: Phase 2 Kidney Disease Trial And Dosing Reset Will Drive Upside
Narrative Update Akebia Therapeutics' consensus analyst price target has shifted from about $5 to roughly $4.40, as analysts factor in the recent US Renal Care dosing protocol change and its impact on Vafseo channel inventory and recognized Q4 revenue. Analyst Commentary Recent research updates reflect a mixed read on Akebia Therapeutics, with targets adjusted to roughly US$4, as analysts factor in the new US Renal Care dosing protocol and its effect on Vafseo revenue recognition in Q4.Anlatı Güncellemesi • Feb 21
AKBA: Rare Kidney Pipeline Progress Will Support Stronger Long Term Profitability
Analysts have reduced their Akebia Therapeutics price target by $3, citing a lower fair value estimate, a higher discount rate, and a shift to expectations of declining revenue growth. This is partly offset by a slightly stronger profit margin outlook and a lower assumed future P/E multiple.Anlatı Güncellemesi • Feb 07
AKBA: Phase 2 Kidney Disease Pipeline Progress Will Drive Substantial Upside
Analysts have trimmed their fair value estimate for Akebia Therapeutics from US$5.40 to US$5.00, citing updated assumptions for growth, profitability and a higher future P/E multiple reflected in recent Street research, including the lowered Piper Sandler price target. Analyst Commentary Recent research around Akebia Therapeutics has focused on how updated growth and profitability assumptions feed into valuation, including the trimmed fair value estimate and a reset price target.Anlatı Güncellemesi • Jan 24
AKBA: Rare Kidney Disease Pipeline Progress Will Drive Future Upside
Analysts now set their price target for Akebia Therapeutics at US$6.00, unchanged from the prior US$6.00. This reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E that largely offset each other in their valuation work.Anlatı Güncellemesi • Jan 10
AKBA: Rare Kidney Pipeline And Anemia Data Will Support Future Upside
Analysts have adjusted their price target on Akebia Therapeutics to US$6.00 from US$6.00, reflecting updated assumptions around the discount rate, expected revenue growth, profit margin and a slightly higher future P/E multiple. What's in the News Akebia dosed the first patient in a Phase 2 randomized, double blind, placebo controlled trial of praliciguat for biopsy confirmed focal segmental glomerulosclerosis.Anlatı Güncellemesi • Dec 26
AKBA: Rare Kidney Pipeline Progress Will Drive Future Share Upside
Analysts have nudged their price target for Akebia Therapeutics slightly higher to 6.00 dollars per share from 6.00 dollars previously, reflecting modestly improved long term assumptions around revenue growth, profit margins, and the companys risk profile. What's in the News Akebia has initiated Phase 2 clinical development of praliciguat for focal segmental glomerulosclerosis, triggering an expected 1.0 million dollar regulatory milestone payment to Cyclerion when the first patient is dosed, anticipated in 2026 (Key Developments).Anlatı Güncellemesi • Dec 12
AKBA: Rare Kidney Franchise Will Drive Future Share Upside Despite Higher Risk
Analysts have reduced their fair value estimate for Akebia Therapeutics from 10.00 dollars to 6.00 dollars, citing a higher perceived risk profile. This is reflected in an increased discount rate and a lower future earnings multiple, even as long term revenue growth and margin expectations edge higher.Anlatı Güncellemesi • Nov 28
AKBA: European Partnership And Clinical Data Will Drive Substantial Upside
Analysts have slightly lowered their price target for Akebia Therapeutics from $5.50 to $5.40, citing updated financial forecasts, as well as expectations for improved profit margins and revenue growth. What's in the News Akebia Therapeutics and Medice amended their License Agreement and granted Medice the right to manufacture Vafseo tablets for anemia in chronic kidney disease patients in Europe.Anlatı Güncellemesi • Nov 13
AKBA: Broad U.S. Launch In 2025 Will Drive Upside Potential
Analysts have lowered their price target for Akebia Therapeutics from $6.80 to $5.50, citing moderated expectations for revenue growth and profitability. What's in the News Akebia Therapeutics presented a post-hoc win odds analysis from the Phase 3 INNO2VATE trials of vadadustat, showing favorable effects of Vafseo compared to darbepoetin alfa on death or hospitalization in dialysis patients.Analiz Makalesi • Nov 04
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Unfortunately for some shareholders, the Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) share price has dived 25% in the...Anlatı Güncellemesi • Oct 30
AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside
Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.Analiz Makalesi • Aug 10
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
NasdaqCM:AKBA 1 Year Share Price vs Fair Value Explore Akebia Therapeutics's Fair Values from the Community and select...Analiz Makalesi • Jun 18
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...Analiz Makalesi • May 10
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) had a good week, as its shares rose 4.1% to close at US$2.55...Analiz Makalesi • May 04
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders would be excited to see that the share price has had a great...
Yeni Anlatı • Apr 28
Vafseo And VALOR Study Will Open New Treatment Markets
Early success of Vafseo and reimbursement coverage expansion likely to drive strong revenue growth and market access.Analiz Makalesi • Mar 20
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33%
Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have continued their recent momentum with a 33% gain in the last month...Analiz Makalesi • Mar 16
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83
Shareholders of Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) will be pleased this week, given that the stock price is up...Analiz Makalesi • Jan 22
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Analiz Makalesi • Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%
Despite an already strong run, Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shares have been powering on, with a gain of...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 202 | -28 | -38 | -59 | 4 |
| 12/31/2027 | 160 | -78 | -59 | -72 | 5 |
| 12/31/2026 | 207 | -40 | -31 | -43 | 5 |
| 3/31/2026 | 232 | -21 | 52 | 60 | N/A |
| 12/31/2025 | 236 | -5 | 60 | 68 | N/A |
| 9/30/2025 | 225 | -16 | 32 | 32 | N/A |
| 6/30/2025 | 204 | -36 | -3 | -2 | N/A |
| 3/31/2025 | 185 | -45 | -35 | -35 | N/A |
| 12/31/2024 | 160 | -69 | -41 | -41 | N/A |
| 9/30/2024 | 170 | -46 | -39 | -39 | N/A |
| 6/30/2024 | 174 | -40 | -39 | -39 | N/A |
| 3/31/2024 | 187 | -43 | -25 | -25 | N/A |
| 12/31/2023 | 195 | -52 | -23 | -23 | N/A |
| 9/30/2023 | 194 | -59 | -76 | -76 | N/A |
| 6/30/2023 | 201 | -98 | -35 | -35 | N/A |
| 3/31/2023 | 271 | -58 | -69 | -69 | N/A |
| 12/31/2022 | 292 | -94 | -73 | -73 | N/A |
| 9/30/2022 | 294 | -158 | -81 | -81 | N/A |
| 6/30/2022 | 294 | -163 | -171 | -171 | N/A |
| 3/31/2022 | 221 | -276 | -204 | -204 | N/A |
| 12/31/2021 | 212 | -282 | -253 | -253 | N/A |
| 9/30/2021 | 211 | -299 | -221 | -221 | N/A |
| 6/30/2021 | 222 | -300 | -192 | -192 | N/A |
| 3/31/2021 | 259 | -392 | -92 | -92 | N/A |
| 12/31/2020 | 295 | -385 | -111 | -110 | N/A |
| 9/30/2020 | 308 | -391 | -172 | -172 | N/A |
| 6/30/2020 | 340 | -386 | -136 | -134 | N/A |
| 3/31/2020 | 351 | -268 | -214 | -209 | N/A |
| 12/31/2019 | 335 | -280 | N/A | -257 | N/A |
| 9/30/2019 | 325 | -245 | N/A | -239 | N/A |
| 6/30/2019 | 286 | -217 | N/A | -262 | N/A |
| 3/31/2019 | 234 | -193 | N/A | -215 | N/A |
| 12/31/2018 | 208 | -144 | N/A | -97 | N/A |
| 9/30/2018 | 238 | -68 | N/A | -40 | N/A |
| 6/30/2018 | 227 | -65 | N/A | -82 | N/A |
| 3/31/2018 | 206 | -53 | N/A | -67 | N/A |
| 12/31/2017 | 181 | -74 | N/A | -56 | N/A |
| 9/30/2017 | 92 | -127 | N/A | 56 | N/A |
| 6/30/2017 | 51 | -140 | N/A | 82 | N/A |
| 3/31/2017 | 22 | -154 | N/A | 31 | N/A |
| 12/31/2016 | 2 | -136 | N/A | 58 | N/A |
| 9/30/2016 | N/A | -118 | N/A | -61 | N/A |
| 6/30/2016 | N/A | -101 | N/A | -41 | N/A |
| 3/31/2016 | N/A | -76 | N/A | -27 | N/A |
| 12/31/2015 | N/A | -61 | N/A | -52 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: AKBA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: AKBA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: AKBA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: AKBA şirketinin gelirinin (yıllık 2.5% ) US pazarından (yıllık 12.8% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: AKBA şirketinin gelirinin (yıllık 2.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: AKBA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/01 21:39 |
| Gün Sonu Hisse Fiyatı | 2026/07/01 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Akebia Therapeutics, Inc. 17 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Julian Harrison | BTIG |
| Michael King | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |